Innate immune dysfunction in inflammatory bowel disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Gersemann M, Wehkamp J, Stange EF (Robert Bosch Hospital, Stuttgart; Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen; Germany). Innate immune dysfunction in inflammatory bowel disease (Review). J Intern Med 2012; 271: 421–428. The pathogenetic mechanisms that cause the two types of inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), are still under investigation. Nevertheless, there is broad agreement that luminal microbes are of particular relevance in the development of these conditions. In recent years, increasing evidence has shown that defects in the innate immunity are at the centre of both types of IBD. The innate intestinal barrier is provided by the epithelium which secretes antimicrobial peptides (so‐called defensins) that are retained in the mucus layer. In ileal CD, the alpha‐defensins are lacking owing to several Paneth cell defects. In colonic CD, the expression of beta‐defensins is inadequate. This may be related to downregulation of the transcription factor peroxisome proliferator‐activated receptor‐gamma and in some cohorts is associated with a reduced HBD2 gene copy number. In UC, the mucus layer, which protects the host from the enormous amounts of luminal microbes, is defective. This is accompanied by an insufficient differentiation from intestinal stem cells towards goblet cells. All these disturbances in the gut barrier shift the balance from epithelial defence towards bacterial offence. The current treatment for CD and UC is based on suppression of this secondary inflammatory process. In future, patients may benefit from new therapeutic approaches stimulating the protective innate immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Png, C. W., Lindén, S. K., Gilshenan, K. S., Zoetendal, E. G., McSweeney, C. S., Sly, L. I., McGuckin, M. A., & Florin, T. H. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.281 · Cited by 1,364
Microbial modulation of innate defense: goblet cells and the intestinal mucus layer
Deplancke, B., & Gaskins, H. R. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.6.1131s · Cited by 1,012
Swidsinski, A., Weber, J., Loening-Baucke, V., Hale, L. P., & Lochs, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3380-3389.2005 · Cited by 894
Trichuris suis therapy in Crohn’s disease
Summers, R. W., Elliott, D. E., Urban, J. F., Thompson, R., & Weinstock, J. V. (2005) · Gut · doi:10.1136/gut.2004.041749 · Cited by 762
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743
The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases
Chassaing, B., & Darfeuille–Michaud, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.054 · Cited by 443
Cited by
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
“Ileal CD is associated with a decreased production of Paneth alpha-defensins in response to sensing of microbes by pattern-recognition of commensal bacteria and pathogens, whereas colonic CD is associated with a reduced expression of HBD1 and a reduced induction of HBD2 and HBD3 also resulting in a reduced mucosal def…”
BackgroundThe intestinal epithelium: central coordinator of mucosal immunity
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J., & Vallance, B. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.002 · Cited by 933
Michielan, A., & D’Incà, R. (2015) · Mediators of Inflammation · doi:10.1155/2015/628157 · Cited by 709
“Indeed, the diminished Paneth cell antimicrobial function might be a primary pathogenic factor in CD, particularly ileal CD [24, 43, 52, 53], while the increased secretion of defensins in UC may be a physiological response to mucosal damage.”
BackgroundNishino, K., Nishida, A., Inoue, R., Kawada, Y., Ohno, M., Sakai, S., Inatomi, O., Bamba, S., Sugimoto, M., Kawahara, M., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1384-4 · Cited by 463
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Metadata
- Authors
- Gersemann, M., Wehkamp, J., & Stange, E. F.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2012-02-13
- Volume
- 271
- Issue
- 5
- Pages
- 421-428
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2119573240
- Cited by
- 143
- References
- 10
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.